SKIBSTED RUSSELL 4

What Happened

• Russell Skibsted, Chief Financial Officer of Processa Pharmaceuticals, reported acquiring 2,324 shares of PCSA on 2026-03-31. The shares were purchased at $2.54 per share for a total transaction value of approximately $5,891. The transaction is reported under purchase code "P" (open-market or private purchase).

Key Details

• Transaction date: 2026-03-31
• Price per share: $2.54; Total value: ~$5,891
• Report filed with the SEC: Form 4 filed 2026-04-01 (timely)
• Transaction code: P (purchase — reported as open-market/private purchase)
• Shares owned after the transaction: not specified in the provided filing excerpt
• Accession: 0000897069-26-000754 (Form 4)

Context

• Insider purchases are often watched by investors as a sign of confidence, but this purchase is relatively small in dollar terms (~$5.9K). The filing appears timely and contains no special footnotes (e.g., 10b5‑1 plan or tax withholding) in the provided details.